Riliprubart is under clinical development by Sanofi and currently in Phase III for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to GlobalData, Phase III drugs for Chronic ...
Efgartigimod alfa is under clinical development by Argenx and currently in Pre-Registration for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to GlobalData, Pre-Registration ...
Funding from M&T Charitable Foundation will allow Luzerne County Head Start to provide care packages to children and families in need. M&T presented Luzerne County Head Start with a $5,000 check ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterized by immune-mediated peripheral nerve and nerve root dysfunction. In patients with this disorder, cancer remains a significant ...
FDA adds warning label to RSV vaccines Abrysvo and Arexvy about the risk for Guillain-Barré syndrome
Get Instant Summarized Text (Gist) The FDA has mandated safety labeling changes for the RSV vaccines Abrysvo and Arexvy to include warnings about the risk of Guillain-Barré syndrome (GBS ...
To assess the risk of GBS with these vaccines, the FDA conducted a postmarketing observational study that used Medicare claims data between May 2023 and July 2024. Individuals aged 65 years and older ...
In nominating Andy Puzder as Ambassador to the European Union, President Trump has made a bold and strategic choice. Andy’s proven leadership as a business executive, coupled with his profound ...
Opens in a new tab or window The prescribing information for each vaccine has been revised to say that a postmarketing observational study suggested an increased risk of GBS in the 42 days ...
In deliberating its recommendations for the shots, the CDC’s Advisory Committee on Immunization Practices discussed data suggesting there was an increased risk for GBS. Although it said an ...
The directive follows a post-marketing study by the regulator, which found that patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo are at greater risks of developing GBS, a rare neurological ...
Background: Little is known about the long term prognosis for patients the severe acute motor axonal neuropathy (AMAN) form of Guillain–Barré syndrome (GBS), unlike those with acute inflammatory ...
ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study [IGOS] Matched Cohort Study Showed Early and Greater Benefits of ANX005 over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback